<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621929</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202001895-A-N</org_study_id>
    <secondary_id>1R21DK122317-01A1</secondary_id>
    <nct_id>NCT04621929</nct_id>
  </id_info>
  <brief_title>Obesity and Uric Acid Stones Study</brief_title>
  <official_title>Phentermine/tOpiramate to eND Obesity and Uric Acid Stones Trial (POuND OUT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator proposes an 18 month, feasibility pilot study, randomizing obese and&#xD;
      diabetic individuals with pure uric acid nephrolithiasis (UAN) or mixed calcium oxalate (CO)&#xD;
      UAN to either phentermine/topiramate or a pragmatic control group who will remain on their&#xD;
      standard medication regimen (citrate salts, allopurinol, diet, etc.).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mounting evidence indicates that obesity, diabetes mellitus, and kidney stones are&#xD;
      inter-connected diseases, particularly uric acid nephrolithiasis (UAN) with or without&#xD;
      components of calcium oxalate (CO). Obese or overweight diabetics have a six-fold increased&#xD;
      risk to develop UAN/COUAN due to the inability to properly add buffer (ammonium) to urine. Of&#xD;
      the FDA approved drugs in the weight loss market, the combination medication phentermine/&#xD;
      topiramate is the most effective and has a unique side effect of alkalinizing the urine&#xD;
      (making it less acidic). The hypothesize of this project is that treatment of obese, diabetic&#xD;
      patients with phentermine/topiramate will reduce the incidence of UAN/COUAN by 1) direct&#xD;
      urinary alkalinization and 2) weight loss. Weight loss will indirectly improve urinary&#xD;
      buffering ability through improvement in insulin sensitivity and will decrease renal&#xD;
      oxidative stress. The investigative team proposes an 18 month, feasibility pilot study,&#xD;
      randomizing 30 obese and diabetic individuals with UAN/COUAN to either phentermine/topiramate&#xD;
      (n=20) or a pragmatic control group (n=10) who would remain on standard medication regimen&#xD;
      (citrate salts, allopurinol, diet, etc).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">April 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 ratio block site of 6</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney stone growth (mm2) as determined by non-contrast CT scan</measure>
    <time_frame>18 months</time_frame>
    <description>Existing kidney stone growth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New kidney stone formation (mm2) as determined by non-contrast CT scan</measure>
    <time_frame>18 months</time_frame>
    <description>Formation of a new kidney stone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>18 months</time_frame>
    <description>Expressed as total percent body weight loss (total weight loss in pounds/starting weight in pounds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary pH parameters</measure>
    <time_frame>18 months</time_frame>
    <description>Absolute change in urine pH (end of study compared to baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin A1c</measure>
    <time_frame>18 months</time_frame>
    <description>Percent change in A1c (end of study compared to baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary citrate parameters</measure>
    <time_frame>18 months</time_frame>
    <description>Percent change in urinary citrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary calcium parameters</measure>
    <time_frame>18 months</time_frame>
    <description>Percent change in urinary calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary uric acid parameters</measure>
    <time_frame>18 months</time_frame>
    <description>Percent change in urinary uric acid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Obesity</condition>
  <condition>Uric Acid Stones</condition>
  <condition>Type 2 Diabetes Mellitus in Obese</condition>
  <condition>Pre-Diabetes</condition>
  <arm_group>
    <arm_group_label>Allocated to intervention/treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily phentermine/topiramate x 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allocated to pragmatic control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remain on their current regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine / Topiramate Oral Product</intervention_name>
    <description>All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)</description>
    <arm_group_label>Allocated to intervention/treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Citrate Salts, Allopurinol, Diet</intervention_name>
    <description>Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.</description>
    <arm_group_label>Allocated to pragmatic control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  have recurrent pure uric acid nephrolithiasis (UAN) or mixed calcium oxalate (CO)/UAN.&#xD;
             Recurrent stone disease is defined as at least two spontaneous kidney stone passages,&#xD;
             two previous kidney stone procedures, or one previous stone passage and one previous&#xD;
             procedure. Pure UAN is defined as at least one previous stone analysis demonstrating&#xD;
             100% uric acid mineral content. Mixed COUAN will be defined as at least one previous&#xD;
             stone analysis with any mix of uric acid ≥80% and ≤20% calcium oxalate. If participant&#xD;
             has more than one stone analysis, the most recent will be considered the current stone&#xD;
             type.&#xD;
&#xD;
          -  have obesity, defined as BMI &gt; 30 kg/m2.&#xD;
&#xD;
          -  have type 2 diabetes mellitus or pre-diabetes, defined as previously diagnosed by&#xD;
             laboratory testing (hemoglobin A1c, fasting plasma glucose, or oral glucose tolerance&#xD;
             test) or as demonstrated by use of anti-hyperglycemic medications or insulin.&#xD;
&#xD;
          -  have at least one 24-hour urine study off medications demonstrating urine pH &lt; 5.8 or&#xD;
             a study 24-hr urine demonstrating urine pH &lt; 5.8&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications to topiramate, including: recurrent major depression, current&#xD;
             substantial depressive symptoms, uncontrolled depression by PHQ 9 score &gt;= 10, history&#xD;
             of suicidal ideation or behavior with intent to act (versus exclude those with&#xD;
             depression); current pregnancy or attempting to conceive; pre-existing chronic kidney&#xD;
             disease with eGFR &lt; 60 at time of enrollment; active cancer or active treatment for&#xD;
             cancer (chemotherapy, radiation); and non-ambulatory.&#xD;
&#xD;
          -  contraindications to phentermine, including: unstable cardiovascular disease defined&#xD;
             as decompensated heart failure, unstable angina, atrial fibrillation, uncontrolled&#xD;
             blood pressure (&gt;160 systolic), hyperthyroidism; monoamine oxidase inhibitor use;&#xD;
             current history of drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Canales, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Marks</last_name>
    <phone>352-273-5618</phone>
    <email>marksjg@ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Marks</last_name>
      <phone>352-273-5618</phone>
      <email>marksjg@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Canales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

